Efficacy and Safety of Intralesional Corticosterois in the Treatment of Vitiligo
Status:
Unknown status
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
Vitiligo is a chronic acquired disease characterized by well defined white macules and
patches affecting the skin. It has a major psychosocial impact on affected patients. There
are many treatment modalities available for vitiligo, however, none of them cure the disease.
Topical corticosteroids (CS) are the most effective monotherapy for localized vitiligo.
Treatment with intralesional corticosteroids (ILCS) is commonly used in many dermatologic
conditions. However, there are only a few studies published on the use of ILCS in vitiligo.
This is a prospective double-blind randomized clinical trial to assess efficacy and safety of
ILCS in the treatment of vitiligo. Four treatment sessions will be done over 4 to 6 months.
The investigators will compare intralesional triamcinolone acetonide (active treatment) to
normal saline (placebo).